Association of specific cytogenetic aberrations with mdr1 gene expression in adult myeloid leukemia and its implication in treatment outcome.

BACKGROUND AND OBJECTIVES

Cytogenetics and mdr1 expression are established prognostic factors for treatment outcome in adult acute myeloid leukemia (AML). The association, however, between specific cytogenetic aberrations and mdr1 expression has not yet been examined in a large cohort of patients.

DESIGN AND METHODS

We therefore looked for mdr1 gene expression at diagnosis within specific cytogenetic aberrations in 331 previously untreated adult patients with de novo or secondary AML (not including t(15;17)) entered into the German SHG AML96 treatment trial.

RESULTS

The proportion of mdr1 positive blast probes was significantly higher in patients with aberrant karyotypes than in those with normal karyotypes (39% vs. 15%; p<0.001). Looking at specific cytogenetic aberrations significantly more mdr1 positive AML patients were found within t(8;21), +8, +21, del(7q), del(5q), -7, abn(3q) and multiple aberrations. In contrast, no patient with inv(16) was positive for mdr1. Only 26% of mdr1 positive patients with aberrant karyotypes achieved complete remission (CR) whereas 54% of the mdr1 negative counterparts did so (p=0.002). Furthermore, within abn(11q), +21, +22, -5 or abn(3q) no mdr1 positive patient reached CR, whereas the mdr1 negative counterparts had CR rates comparable to the CR rate of patients with a normal karyotype. This was most impressive in mdr1 negative patients with multiple aberrations achieving a CR rate of 63% (p=0.019). In the multivariate analysis age, disease status and mdr1 expression were the strongest independent predictors for induction treatment failure.

INTERPRETATION AND CONCLUSIONS

The correlation described here between mdr1 gene expression and some cytogenetic aberrations might explain the prognostic divergence of such cytogenetic aberrations in different AML treatment trials due to the amount of mdr-drugs used within the protocols.